GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bright Minds Biosciences Inc (XCNQ:DRUG) » Definitions » EPS without NRI

Bright Minds Biosciences (XCNQ:DRUG) EPS without NRI : C$-1.80 (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Bright Minds Biosciences EPS without NRI?

Bright Minds Biosciences's earnings per share without non-recurring items for the three months ended in Dec. 2023 was C$-0.44. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was C$-1.80.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -74.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Bright Minds Biosciences's EPS without NRI or its related term are showing as below:

XCNQ:DRUG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -74.2   Med: -74.2   Max: -74.2
Current: -74.2

During the past 4 years, Bright Minds Biosciences's highest 3-Year average Earnings Per Share (NRI) Growth Rate was -74.20% per year. The lowest was -74.20% per year. And the median was -74.20% per year.

XCNQ:DRUG's 3-Year EPS without NRI Growth Rate is ranked worse than
95.14% of 1296 companies
in the Biotechnology industry
Industry Median: 4.8 vs XCNQ:DRUG: -74.20

Bright Minds Biosciences's EPS (Diluted) for the three months ended in Dec. 2023 was C$-0.44. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was C$-1.78.

Bright Minds Biosciences's EPS (Basic) for the three months ended in Dec. 2023 was C$-0.44. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was C$-1.78.


Bright Minds Biosciences EPS without NRI Historical Data

The historical data trend for Bright Minds Biosciences's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bright Minds Biosciences EPS without NRI Chart

Bright Minds Biosciences Annual Data
Trend Sep20 Sep21 Sep22 Sep23
EPS without NRI
-0.38 -4.91 -6.06 -1.98

Bright Minds Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.64 -0.55 -0.39 -0.42 -0.44

Competitive Comparison of Bright Minds Biosciences's EPS without NRI

For the Biotechnology subindustry, Bright Minds Biosciences's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bright Minds Biosciences's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bright Minds Biosciences's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Bright Minds Biosciences's PE Ratio without NRI falls into.



Bright Minds Biosciences EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bright Minds Biosciences  (XCNQ:DRUG) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Bright Minds Biosciences EPS without NRI Related Terms

Thank you for viewing the detailed overview of Bright Minds Biosciences's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Bright Minds Biosciences (XCNQ:DRUG) Business Description

Traded in Other Exchanges
Address
19 Vestry Street, New York, NY, USA, 10013
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.